We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+31.13%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$4.73B
AUM Growth
+$575M
Cap. Flow
-$186M
Cap. Flow %
-3.94%
Top 10 Hldgs %
46.08%
Holding
127
New
17
Increased
23
Reduced
25
Closed
19

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$95.5M
2
VKTX icon
Viking Therapeutics
VKTX
+$57.4M
3
ARGX icon
argenx
ARGX
+$52.2M
4
ADGM
Adagio Medical Holdings
ADGM
+$46.7M
5
ORKA
Oruka Therapeutics
ORKA
+$43M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$441M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$74.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$60M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$38.8M
5
SWTX
SpringWorks Therapeutics
SWTX
+$35.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EWTX icon
26
Edgewise Therapeutics
EWTX
$4.74B
$62.2M 1.32%
2,330,294
+473,877
+26% +$9.43M
PTGX icon
27
Protagonist Therapeutics
PTGX
$9.74B
$61.9M 1.31%
1,374,563
+105,828
+8% +$4.28M
MGTX icon
28
MeiraGTx Holdings
MGTX
$1.39B
$52.4M 1.11%
12,581,103
+1,250,000
+11% +$5.4M
ALDX icon
29
Aldeyra Therapeutics
ALDX
$94.1M
$50M 1.06%
9,275,851
– –
AKRO
30
DELISTED
Akero Therapeutics
AKRO
$49.2M 1.04%
1,714,806
+214,909
+14% +$5.6M
SLDB icon
31
Solid Biosciences
SLDB
$1.04B
$48.1M 1.02%
6,906,646
– –
TARS icon
32
Tarsus Pharmaceuticals
TARS
$3.1B
$42.6M 0.9%
1,296,416
– –
XBI icon
33
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.7B
$39.5M 0.84%
+400,000
New +$39.3M
ACRV icon
34
Acrivon Therapeutics
ACRV
$90.4M
$37.5M 0.79%
5,360,858
– –
CRNX icon
35
Crinetics Pharmaceuticals
CRNX
$9B
$37M 0.78%
724,698
-751,505
-51% -$38.8M
NAUT icon
36
Nautilus Biotechnolgy
NAUT
$119M
$35.9M 0.76%
12,594,211
– –
CELC icon
37
Celcuity
CELC
$4.56B
$35.2M 0.75%
2,362,279
– –
PODD icon
38
Insulet
PODD
$9.9B
$33.1M 0.7%
+142,269
New +$29.2M
ORKA
39
Oruka Therapeutics
ORKA
$6.71B
$30.3M 0.64%
+1,235,187
New +$43M
CTNM
40
Contineum Therapeutics
CTNM
$629M
$29M 0.61%
1,516,668
-50,000
-3% -$959K
OCUL icon
41
Ocular Therapeutix
OCUL
$2.38B
$28.9M 0.61%
3,324,468
– –
ISRG icon
42
Intuitive Surgical
ISRG
$130B
$28.6M 0.6%
58,119
-3,681
-6% -$1.71M
NTRA icon
43
Natera
NTRA
$48.9B
$27.9M 0.59%
220,000
-310,000
-58% -$35.6M
CGON icon
44
CG Oncology
CGON
$6.94B
$27.7M 0.59%
733,695
– –
ZYME icon
45
Zymeworks
ZYME
$2.12B
$27.4M 0.58%
2,180,020
+512,309
+31% +$5.58M
DYN icon
46
Dyne Therapeutics
DYN
$4.85B
$25.8M 0.55%
+718,144
New +$28.6M
ADGM
47
Adagio Medical Holdings
ADGM
$12.2M
$25.3M 0.54%
+9,812,419
New +$46.7M
ARVN icon
48
Arvinas
ARVN
$612M
$25.3M 0.54%
1,027,749
– –
PRCT icon
49
Procept Biorobotics
PRCT
$1.21B
$25.3M 0.54%
315,659
+105,000
+50% +$7.46M
NBIX icon
50
Neurocrine Biosciences
NBIX
$15.7B
$24.5M 0.52%
212,228
-437,681
-67% -$60M
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Perceptive Advisors held 127 positions worth $4.73B, up 14% from $4.15B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors withdrew a net $186M in Q3 2024, closing 19 positions and reducing 25 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $441M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Adagio Medical Holdings worth $25.3M.

  • Perceptive Advisors's largest Q3 2024 buy was Adagio Medical Holdings: 9,812,419 shares worth $25.3M.
  • Perceptive Advisors added most to Verona Pharma in Q3 2024, an estimated $95.5M increase.
  • Perceptive Advisors's biggest Q3 2024 reduction was Neurocrine Biosciences, cutting an estimated $60M.
  • Perceptive Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $441M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $4.73B portfolio in Q3 2024.
  • Perceptive Advisors opened 17 new positions and closed 19 in Q3 2024.
  • Perceptive Advisors's portfolio value rose 14% quarter-over-quarter to $4.73B.

Based on Perceptive Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.